Clinical Trial Detail

NCT ID NCT02127710
Title A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

papillary renal cell carcinoma

Therapies

Savolitinib

Age Groups: adult

No variant requirements are available.